Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From JCO Global Oncology [0.03%]
Long Thanh Nguyen,Celine Hoyek,Akhil Kapoor et al.
Long Thanh Nguyen et al.
By 2045, more than three quarters of global cancer deaths are projected to occur in low- and middle-income countries (LMICs); however, the global availability of cancer care remains constrained by high costs and inequitable access. Value-ba...
Translating Cancer Science Into Cancer Care: Using Serious Illness Communication Frameworks to Deliver High-Quality Person-Centered Care in Neuro-Oncology [0.03%]
转化癌症科学以改善癌症护理：使用严重的疾病交流框架来提供高质量的以患者为中心的神经肿瘤科护理
Heather E Leeper,Kathy Oliver,Helen Bulbeck et al.
Heather E Leeper et al.
People with CNS cancer and their caregivers need and deserve not only innovative cancer-directed care but also high-quality person-centered care for navigating living their lives in the face of their cancer diagnosis and treatment. Palliati...
Unique Considerations in Rare Gynecologic Tumors: Gestational Trophoblastic Neoplasia, Germ Cell Tumors, and Clear Cell Ovarian Cancers [0.03%]
罕见妇科肿瘤的特殊考虑因素：妊娠滋养细胞肿瘤、生殖细胞肿瘤和透明细胞卵巢癌
John H Farley,Keiichi Fujiwara,Jung Yun Lee et al.
John H Farley et al.
Rare cancers are usually defined as an incidence of
Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL [0.03%]
阳性Ph-like基因重排ALL的治疗新理念
Nicholas J Short,Josep-Maria Ribera,Iman Abou Dalle et al.
Nicholas J Short et al.
The treatment of adults with Philadelphia chromosome-positive ALL (Ph+ ALL) has evolved significantly over the past 25 years. These changes have been driven largely by the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs) su...
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer [0.03%]
转移性去势抵抗性前列腺癌患者的治疗优化
Pierre-Yves Cren,James Buteau,Umma Fatema et al.
Pierre-Yves Cren et al.
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved substantially over the past decade, with androgen receptor pathway inhibitors, taxanes, poly (ADP-ribose) polymerase (PARP) inhibitors, radiois...
Right-Sizing Locoregional Management in the Era of Neoadjuvant Therapy for Breast Cancer [0.03%]
新辅助治疗时代的乳腺癌局部区域治疗的优化选择
Stephanie M Wong,Corey Speers,Mark V Schaverien
Stephanie M Wong
The increasing use of neoadjuvant systemic therapy (NAC) has led to a significant paradigm shift in the locoregional treatment of breast cancer, with increasing emphasis on response-guided de-escalation. In current practice, both clinical a...
Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations [0.03%]
精准免疫治疗：以靶向创新手段变革癌症治疗
Myung-Ju Ahn,Bernadett Szabados,Will Ince et al.
Myung-Ju Ahn et al.
While immune checkpoint inhibitors have transformed treatment for many cancers, their benefit remains limited across all tumor types and is constrained by immune-related toxicity. Targeted immunotherapies, including T-cell engagers (TCEs), ...
Tobias Tix,Anita Kumar,Toby A Eyre et al.
Tobias Tix et al.
Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous B-cell malignancy with variable prognosis, ranging from indolent, asymptomatic forms to aggressive subtypes with early treatment failure. Contemporary management emph...
Promising New Platforms and Targets in the Management of Gastroesophageal Cancers [0.03%]
胃食管肿瘤管理中新平台和新靶点的展望
Jeesun Yoon,Caroline Y Chen,Robert Watson et al.
Jeesun Yoon et al.
Gastric and gastroesophageal junction cancers remain a major global cause of cancer-related mortality. Despite incremental advances in surgery and systemic therapy, durable survival gains have been limited, underscoring persistent unmet med...
Beyond Routine Surveillance Imaging for Melanoma: Emerging Technologies for Detecting Early Recurrence and Guiding Clinical Management [0.03%]
超越常规监测成像的黑色素瘤检测新技术：早期复发检测及临床治疗指导方法
Giselle de Souza Carvalho,Cicero Luiz Cunha de Sousa Martins,Kevin Wang et al.
Giselle de Souza Carvalho et al.
Melanoma recurrence risk is highest within the first 2 years after diagnosis and progressively declines thereafter. Current surveillance strategies remain largely guided by clinicopathologic risk stratification, with the comprehensive medic...